LHI1 Stock Overview
A biotechnology company, focuses on developing solutions for Parkinson’s disease in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Algorae Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.046 |
| 52 Week High | AU$0.055 |
| 52 Week Low | AU$0.041 |
| Beta | 0.66 |
| 11 Month Change | -7.92% |
| 3 Month Change | 2.20% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -6.06% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| LHI1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 4.9% | 0.9% |
| 1Y | n/a | -16.6% | 4.2% |
Return vs Industry: Insufficient data to determine how LHI1 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how LHI1 performed against the German Market.
Price Volatility
| LHI1 volatility | |
|---|---|
| LHI1 Average Weekly Movement | 14.3% |
| Biotechs Industry Average Movement | 6.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: LHI1 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine LHI1's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | n/a | David Hainsworth | www.algoraepharma.com |
Algorae Pharmaceuticals Limited, a biotechnology company, focuses on developing solutions for Parkinson’s disease in Australia. It is developing NTCELL, an alginate coated capsule to target the treatment of Parkinson’s disease; and AI-116, a novel combination drug candidate, which includes cannabidiol and an off-patent pharmaceutical ingredient treatment for dementia, including Alzheimer’s disease. The company was formerly known as Living Cell Technologies Limited and changed its name to Algorae Pharmaceuticals Limited in September 2023.
Algorae Pharmaceuticals Limited Fundamentals Summary
| LHI1 fundamental statistics | |
|---|---|
| Market cap | €10.48m |
| Earnings (TTM) | -€1.40m |
| Revenue (TTM) | €26.09k |
401.6x
P/S Ratio-7.5x
P/E RatioIs LHI1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LHI1 income statement (TTM) | |
|---|---|
| Revenue | AU$42.02k |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$42.02k |
| Other Expenses | AU$2.29m |
| Earnings | -AU$2.25m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0013 |
| Gross Margin | 100.00% |
| Net Profit Margin | -5,360.41% |
| Debt/Equity Ratio | 0% |
How did LHI1 perform over the long term?
See historical performance and comparison